Tyra Biosciences (NASDAQ:TYRA) Director Rehan Verjee Buys 972 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Rehan Verjee acquired 972 shares of the stock in a transaction dated Wednesday, September 9th. The stock was acquired at an average cost of $20.58 per share, with a total value of $20,003.76. Following the transaction, the director owned 972 shares of the company’s stock, valued at approximately $20,003.76. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Tyra Biosciences Price Performance

TYRA opened at $22.03 on Friday. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -9.18 and a beta of 0.73. The business has a 50-day moving average of $28.39 and a two-hundred day moving average of $31.84. Tyra Biosciences, Inc. has a 12 month low of $11.82 and a 12 month high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Equities research analysts anticipate that Tyra Biosciences, Inc. will post -2.74 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Tidal Investments LLC acquired a new stake in shares of Tyra Biosciences in the second quarter worth $943,000. WINTON GROUP Ltd purchased a new position in Tyra Biosciences in the second quarter valued at about $537,000. Engineers Gate Manager LP purchased a new stake in shares of Tyra Biosciences in the second quarter worth about $1,021,000. Squarepoint Ops LLC increased its stake in Tyra Biosciences by 211.3% during the 2nd quarter. Squarepoint Ops LLC now owns 63,805 shares of the company’s stock worth $2,038,000 after buying an additional 43,311 shares during the period. Finally, California State Teachers Retirement System lifted its stake in shares of Tyra Biosciences by 55,815.5% in the second quarter. California State Teachers Retirement System now owns 783,935 shares of the company’s stock worth $24,544,000 after acquiring an additional 782,533 shares in the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Key Tyra Biosciences News

Here are the key news stories impacting Tyra Biosciences this week:

• Positive Sentiment: Initial SURF302 results support further development of dabogratinib in bladder cancer, providing evidence of potential activity for Tyra’s lead program. The Pharma Letter article
• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating and maintained a $53 price target, signaling substantial potential upside if the clinical program succeeds. Benzinga analyst rating report
• Positive Sentiment: Director Rehan Verjee purchased 972 shares for approximately $20,004 at an average price of $20.58. The insider purchase may be viewed as a signal of confidence, although its size is modest relative to the company’s market value. SEC insider ownership filing
• Neutral Sentiment: Reported short-interest data showed zero shares sold short and a zero-day short-interest ratio, but the figures appear anomalous and provide little useful information about trading sentiment.
• Negative Sentiment: Coverage indicated that bladder-cancer response rates from SURF302 were below investor expectations, creating uncertainty about dabogratinib’s commercial and regulatory potential. BioSpace article
• Negative Sentiment: HC Wainwright lowered its price target from $45 to $30, although it retained a “Buy” rating, reflecting reduced near-term expectations following the trial update. Benzinga analyst rating report
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of TYRA investors, adding a legal and reputational overhang. The announcement did not establish wrongdoing by Tyra. Pomerantz investor alert

Wall Street Analyst Weigh In

TYRA has been the topic of a number of recent analyst reports. Bank of America increased their price target on shares of Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Tyra Biosciences in a research note on Thursday. HC Wainwright dropped their price objective on Tyra Biosciences from $45.00 to $30.00 and set a “buy” rating for the company in a report on Thursday. JonesTrading began coverage on Tyra Biosciences in a research report on Wednesday, June 17th. They issued a “buy” rating and a $56.00 target price on the stock. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $42.00 target price on shares of Tyra Biosciences in a report on Wednesday, August 5th. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.88.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.